Also called personalized medicine, this evolving field makes use of an individual’s genes, lifestyle, environment and other factors to identify unique disease risks and guide treatment decision-making.
Masimo's MightySat Medical is the first FDA-cleared pulse oximeter available to consumers without a prescription, which could disrupt the market for the notoriously inaccurate at-home devices.
MediView’s technologies utilize AR to provide clinicians with 3D “X-ray vision” guidance during minimally invasive procedures and surgeries, while also offering remote collaboration.
The updated, final Federal Health IT Strategic Plan 2015-2020 was released by the Office of the National Coordinator for Health IT (ONC) and reflects input from more than 400 public comments, collaboration between federal contributors and recommendations from the Health IT Policy Committee.
Jodi Daniel, JD, MPH, director of the Office of the National Coordinator for Health IT (ONC)’s Office of Policy, is leaving the federal agency, effective Oct. 9.
Membership in the CommonWell Health Alliance keeps climbing. Another four health IT companies have signed on for a total membership of 33 organizations.
More than 165,000 mobile health apps are now available to consumers, according to a report published by the IMS Institute for Healthcare Informatics.
The American Society for Clinical Oncology has issued a position statement urging Congress to pass legislation that would strengthen interoperability of EHRs.
Mayo Clinic and AVIA, a Chicago-based provider-led accelerator, have announced the six finalists who will be competing in Mayo's inaugural THINK BIG Challenge.
The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.
The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks.
Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.
